Recently, it has been shown that the addition of Vitamin C in pharmacologic concentrations selectively kills KRAS mutant cells, resulting in the downregulation of both GLUT1- and PKM2-dependent protein expression, suggesting its positive role in anti-tumour therapies [22,24]. This evidence concerns the gene SLC2A1 and neoplasm.